• Like
Upcoming SlideShare
Loading in...5


Uploaded on


  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads


Total Views
On Slideshare
From Embeds
Number of Embeds



Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

    No notes for slide


  • 1. THE UNIVERSITY OF NOTTINGHAM SCHOOL OF MOLECULAR MEDICAL SCIENCES Lecturer in Human Molecular Genetics Introduction Candidates are invited to apply for a lectureship in Human Molecular Genetics in the School of Molecular Medical Sciences (MOL), which is located within the Faculty of Medicine and Health Sciences at the University of Nottingham. The aims of the post is to co-ordinate and teach the new MSc course in Molecular Diagnostics and to develop a competitive, externally-funded, research programme in and of human genetics that fit in with the research activities of the Institute of Genetics. The appointee will be expected to have research interests that complement those in the area of human genetic. Teaching in the School at undergraduate level involves lectures (both at Queen’s Medical Centre (QMC) and the Graduate Entry Medical course at Derby) and project supervision of medical students. The School runs five successful MSc courses in Clinical Oncology, Cancer Immunotherapy, Molecular Immunology, Molecular Medical Microbiology and in Clinical Microbiology which attract over 100 students per year. The main remit of the new lecturer is to take charge of co-ordinating and running the newly created MSc course in Molecular Diagnostics, with the assistance of a research technician, the school’s postgraduate teaching administrator and MSc course secretaries. This will include the teaching and supervision of students, student recruitment, building a network of project supervisors and utilizing the existing MSc database administration system. Recently there has been a major administrative reorganisation within the Faculty in order to establish a sustainable and expanding research base. MOL incorporates the Divisions of Clinical Chemistry, Clinical Oncology, Haematology, Immunology, Microbiology and Infectious Diseases and Pathology. Research in the Faculty is focused in five institutes, namely the Institutes of i) Genetics ii) Infection, Immunity and Inflammation iii) Neuroscience, iv) Pharmaceutical Sciences and Experimental Therapeutics and (v) Clinical Research. Also, a number of clusters have been established, configured around technology platforms and human resources, including Post Genomic Technologies, Gastroenterology/ Gastrointestinal Research, Imaging Technologies, Stem Cells, Cancer Research, Population Sciences, Respiratory Medicine, Centre of Integrated Systems Biology & Medicine and Centre for Reproduction and Early Life. The majority of academic staff in the School are associated with the Institute of Infection, Immunity & Inflammation (III) and staff in the Division of Clinical Chemistry are all in the Institute of Genetics. Information of on-going research can be found at the following website http://www.nottingham.ac.uk/genetics. There is considerable scope for interactions with strong research groups in the Institute of Genetics and in the School of Molecular Sciences and other units within the University. 1
  • 2. Human Genetics and Plus other areas Within the Human Genetics group there is an emphasis on the role of repetitive DNA sequences in health and disease, and in chromosome stability. Research includes: the molecular basis of myotonic dystrophy and the identification of genes involved in cardiac development; human genetic diversity, copy number analysis; molecular genetics of muscle disease; mouse models of muscle disorders; molecular genetic approaches to anthropology and human population genetics; human genetic variation and susceptibility to complex diseases. • John Armour investigates variation in the human genome, focusing on changes in copy number (DNA deletions and duplications). His group investigates both normal variation in copy number and changes that can lead to genetic diseases. • David Brook works on the molecular genetics of inherited human disorders, in particular, conditions affecting the neuromuscular system and the development of the heart. These studies range from mutation detection in families, to basic molecular analyses that aim to understand fundamental aspects of disease pathophysiology. • Beth Coyle is investigating normal apoptosis during cerebellum development and how this has been subverted in tumours. Apoptosis is a key process in development particularly in the cerebellum where 70% of granule cells (the most abundant type of neuron) die during maturation and in medulloblastoma tumours where cells have overcome this response. • Jane Hewitt studies the molecular mechanisms underlying inherited muscle disease. Her group focuses on muscular dystrophies caused by mutations in genes encoding glycosylation enzymes and a dominant disorder, facioscapulohumeral muscular dystrophy, which is caused by a deletion in a tandem DNA repeat. • Noor Kalsheker studies humoral control of genes of the serine proteinase inhibitor family which regulate key biological pathways and how functional genetic variants contribute to complex diseases such as Alzheimer's disease and chronic lung disease. • Kevin Morgan aims to identify genetic factors that influence susceptibility to Alzheimer's or lung disease, thereby possibly highlighting areas suitable for therapeutic intervention. Genomic and proteomic approaches are being used to identify new candidate genes and biomarkers. • Linda Morgan is investigating the genetic basis of two related disorders of pregnancy - pre-eclampsia and fetal growth restriction. Identification of susceptibility genes provides valuable insights into the mechanism of disease leading to preventative or therapeutic strategies. 2
  • 3. THE UNIVERSITY OF NOTTINGHAM SCHOOL OF MOLECULAR MEDICAL SCIENCES Job Title: Lecturer in Human Molecular Genetics Salary: £28,009 - £37,643 per annum, depending on qualifications and experience. Salary can progress to £43,638 per annum, subject to performance. Location: School of Molecular Medical Sciences/Institute of Genetics Responsible to: Head of School Job Outline: The aim of the post is to take charge of co-ordinating, running and lecturing on the newly created MSc course in Molecular Diagnostics within the School of Molecular Medical Sciences and to develop a competitive, externally-funded, research programme in an area of human genetics. Responsibilities: • Co-ordinating, running and teaching on the MSc course in Molecular Diagnostics. • Contributing to the administration of the school and its teaching programme. • Establishing an independent, internationally competitive research programme. Person Specification: Essential Desirable Qualifications/ PhD or equivalent in a relevant Education subject. Skills/Training Experience in advanced molecular Further bioinformatics skills. biology skills including cloning, cell transfection, high throughput genotyping and basic bioinformatics IT skills. Experience Excellent publication record. Evidence of attracting external Ability to teach at both research funding. undergraduate and postgraduate Evidence of collaboration across level. disciplines Experience of higher education teaching. Experience of developing new methods within the research environment Experience of developing new methods within the research environment.Personal AttributesCommunication skills, both oral and written.OtherFlexible approach to new methods in teaching and research. Informal enquiries may be addressed to Professor R James, Head of School, tel: 0115 8467952, Email: Richard.James@Nottingham.ac.uk or Professor N Kalsheker, Co-Director of the Institute of Genetics, tel: 0115 823 0720, Email: Noor.Kalsheker@Nottingham.ac.uk Please quote ref: TW/274. Closing date: 21 April 2006. 3
  • 4. Peer Reviewed Publications since 2001 1. Lehmann DJ, Wiebusch H, Marshall SE, Johnston C, Morgan K, Schappert K, Poirier J, Kalsheker N, Welsh I, Smith AD (2001). HLA I, II, and III genes in confirmed late-onset Alzheimer’s disease. Neurobiol. Aging, 22: 71-77 2. Henry M, Cave S, Morgan K, O’Connor C, Fitzgerald MX, Kalsheker N (2001). Am alpha-1-antitrypsin enhancer polymorphism is a genetic modifier of pulmonary outcome in cystic fibrosis. Eur. J. Hum. Genet. 9: 273-278. 3. Morgan K, Licastro F, Tilley L, Ritchie A, Pedrini S, Kalsheker N (2001). Polymorphism in the alpha 1-antichymotrypsin (ACT) gene promoter: effect on expression in tranfected glial and liver cell lines and plasma ACT concentrations. Hum. Genet. 109: 303-310 4. Marsters P, Morgan K, Morley S, van Gent D, Hejazi A, Backy M, Thorpe ERG, Kalsheker N (2002). Oncostatin M induced alpha-1-antitrypsin (AAT) gene expression in Hep G2 cells is mediated by a 3' enhancer. Biochem. J. 2002 Jul. 15: 365 (pt 2): 555-60. 5. Plummer S, Morgan L, Kalsheker N. SNPs at the 3' end of the angiotensinogen gene define two haplotypes associated with the common 235Met variant. Am. J. Hum. Genet. 71(2): 443-4. 6. Kalsheker N, Morley S, Morgan K. Gene regulation of the serine proteinase inhibitors alpha-1-antitrypsin and alpha-1-antichymotrypsin. Biochem. Soc. Trans. (2002): 30: 93-98. 7. Brown A, Farmer K, MacDonald L, Kalsheker N, Pritchard D, Haslett C, Lamb J, Sallenave J-M. House dust mite Der p1 down regulates defenses of the lung by inactivating elastase inhibitors. Amer. J. Resp. Cell Mol. Biol. (2003) Vol 29, 381-389. 8. Ling Y, Morgan K, Kalsheker N. Amyloid precursor protein (APP) and the biology of proteolytic processing: relevance to Alzheimer’s disease. Int. J. Biochem. & Cell Biol. (2003) 35: 1505-1535. 9. van Gent D, Sharp P, Morgan K, Kalsheker N. Serpins: structure, function and molecular evolution. Int. J. Biochem. & Cell Biol. (2003) 35: 1536-1547. 10. Licastro F, Chiappelli M, Grimaldi L.M.E., Morgan K, Kalsheker N, et al. A polymorphism in the promoter of alpha-1-antichymotrypsin gene is associated with an increased risk of Alzheimer’s disease and cognitive decline. Neurobiol. Aging. (2004) 11. Plummer S, Tower C, Morgan L, Alonso P, Baker P, Broughton Pipkin F, Kalsheker N. Haplotypes of the angiotensin II receptor genes in women with normotensive pregnancy and women with pre-eclampsia. Hum. Mutat. (2004) 24: 14-20. 12. Plummer S, Guetta-Baranes T, Batowski K, Yiannakis E, Morgan K, O’Connor C, MacNee W, Kalsheker N. Haplotypes of the alpha-1-antitrypsin gene in healthy controls and Z deficient patients. Hum. Mutat. DOI002/Human (2004) 9294. 13. Ritchie A, Morgan K, Kalsheker N. Allele-specific over-expression in astrocytes of an alpha-1-antichymotrypsin promoter polymorphism. Mol. Brain Res. (2004) 131: 88-92. 14. Morgan L et al. Disentangling fetal and maternal susceptibility for pre-eclampsia: A British multicentre candidate gene study. AmerJ. of Hum. Genet. (2005) 77: 127-131. 15.Tower, C; Chappell, S; Acharya, M; Crane, R; Szolin, S; Symonds, L; Chevins, H; Kalsheker, N; Baker, P; Morgan, L. Altered Transmission of Maternal Angiotensin II Receptor Haplotypes in Fetal Growth Restriction. Hum. Mutat. (2006) 27: 138-144. 16.Chappell, S; Daly, L; Morgan, K; Guetta-Baranes, T; Roca, J; Rabinovich, R; Millar, A; Donnelly, S; Keatings, V; MacNee, W; Stolk, J; Hiemstra, P; Miniati, M; Monti, S; O’Connor, C and Kalsheker, N. Cryptic haplotypes of SERPIN A1 confer susceptibility to chronic obstructive pulmonary disease. Hum. Mutat. (2006) 27 (1), 103-109. 17. Baker, C; Neilsen, HM; Minthon, L; Wright, HT; Chappell, S, O’Kyere, J; May, S; Morgan, K; Kalsheker, N; Janciauskiene S. Effects of Alzheimer’s peptide and anti 1- antichymotrypsin on astroyte gene expression. Neurobiol. Aging (in press). 18. Tower CL; Chappell, SL; Morgan, K; Kalsheker, N; Baker, PN; Morgan, L J. Transforming growth factor β1 regulates angiotensin II type I receptor gene expression on the extravillous trophoblast cell line SEHPL-4. Mol. Hum. Reprod, (in 4
  • 5. press). 5